Stock listing

NASDAQ:KTTA Pasithea Therapeutics Corp. Stock

Home listing (NASDAQ) of Pasithea Therapeutics Corp.

Follow Pasithea Therapeutics Corp. into a list and get an email when it puts out news.

Share price · NASDAQ:KTTA

$0.479 USD -0.032 (-6.3%)

Close on Nov 20, 2026

Past year +15.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.470 – $0.515 USDNov 20, 2026
Volume
100,722 sharesNov 20, 2026
Market cap
$16.00M USDAt the close on Nov 20, 2026 · price × 33.41M shares outstanding
52-week range
$0.281 – $2.060 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$354,003 USDMedian day 216,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Pasithea Therapeutics Corp. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KTTA · Home$0.479 USD-0.032 (-6.3%)100,722$0.483$0.515$0.470$0.511Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KTTA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.479-0.032-6.3%$0.483$0.515$0.470100,722
$0.511+0.077+17.6%$0.446$0.538$0.446796,144
$0.434-0.066-13.1%$0.510$0.510$0.4192,079,830
$0.500-0.022-4.2%$0.520$0.520$0.434944,208
$0.522+0.002+0.4%$0.565$0.580$0.4662,353,714
$0.520-0.012-2.3%$0.550$0.550$0.500198,102
$0.532-0.042-7.3%$0.538$0.570$0.525235,408
$0.574+0.031+5.8%$0.543$0.575$0.511473,130
$0.542-0.036-6.3%$0.580$0.610$0.531235,650
$0.579+0.059+11.3%$0.509$0.580$0.505428,725
$0.520-0.010-1.9%$0.536$0.536$0.460659,335
$0.5300.0000.0%$0.525$0.590$0.4812,357,234
$0.530+0.162+44.0%$0.365$0.534$0.34521,753,807
$0.368-0.002-0.5%$0.385$0.399$0.350247,648
$0.3700.0000.0%$0.359$0.389$0.35999,800
$0.370-0.023-5.9%$0.381$0.407$0.350329,700
$0.393-0.004-1.0%$0.391$0.400$0.369596,800
$0.397-0.003-0.8%$0.395$0.425$0.371649,100
$0.400-0.005-1.2%$0.396$0.412$0.372628,900
$0.405-0.040-9.0%$0.450$0.471$0.3451,533,400
$0.445-0.043-8.8%$0.488$0.500$0.445378,800
$0.488+0.078+19.0%$0.425$0.497$0.420774,900
$0.410-0.002-0.5%$0.413$0.415$0.41038,500
$0.412-0.008-1.9%$0.443$0.443$0.41018,500
$0.420+0.010+2.4%$0.410$0.430$0.400209,300
$0.410+0.001+0.2%$0.409$0.438$0.39820,600
$0.409-0.015-3.5%$0.440$0.440$0.383616,500
$0.424-0.024-5.4%$0.450$0.450$0.41060,100
$0.448-0.020-4.3%$0.466$0.466$0.44780,700
$0.468+0.027+6.1%$0.450$0.468$0.45060,600
$0.441-0.002-0.5%$0.452$0.468$0.44156,200
$0.443-0.004-0.9%$0.447$0.468$0.440132,500
$0.447-0.008-1.8%$0.465$0.465$0.44064,100
$0.455-0.021-4.4%$0.486$0.510$0.45584,600
$0.476-0.013-2.7%$0.475$0.509$0.47559,800
$0.489-0.004-0.8%$0.493$0.503$0.48012,000
$0.493+0.003+0.6%$0.489$0.510$0.47760,000
$0.490+0.010+2.1%$0.475$0.496$0.460141,500
$0.480-0.019-3.8%$0.489$0.500$0.452151,200
$0.499-0.015-2.9%$0.500$0.510$0.48594,800
$0.514+0.001+0.2%$0.503$0.530$0.503105,100
$0.513-0.001-0.2%$0.508$0.520$0.502113,900
$0.514+0.004+0.8%$0.530$0.530$0.495165,000
$0.510-0.014-2.7%$0.510$0.517$0.49567,600
$0.524+0.017+3.4%$0.525$0.550$0.488483,200
$0.507+0.017+3.5%$0.490$0.514$0.474238,000
$0.490-0.010-2.0%$0.500$0.510$0.49079,800
$0.500-0.010-2.0%$0.498$0.529$0.491280,400
$0.510-0.020-3.8%$0.523$0.549$0.510135,700
$0.530-0.010-1.9%$0.531$0.552$0.520141,700
$0.540-0.030-5.3%$0.570$0.576$0.520246,900
$0.570-0.029-4.8%$0.599$0.599$0.551210,200
$0.599+0.019+3.3%$0.587$0.600$0.580267,300
$0.5800.0000.0%$0.580$0.593$0.570222,700
$0.5800.0000.0%$0.580$0.595$0.575124,400
$0.580+0.017+3.0%$0.560$0.595$0.550225,700
$0.563-0.011-1.9%$0.557$0.578$0.550216,400
$0.574+0.014+2.5%$0.573$0.586$0.550449,800
$0.560+0.005+0.9%$0.574$0.604$0.534483,900
$0.555-0.015-2.6%$0.576$0.577$0.54966,900
$0.570+0.010+1.8%$0.569$0.580$0.53194,700
$0.560+0.055+10.9%$0.533$0.571$0.525223,840
$0.505-0.034-6.3%$0.523$0.573$0.490339,046
$0.539+0.069+14.7%$0.489$0.539$0.480301,500
$0.470-0.020-4.1%$0.485$0.487$0.470108,000

Splits

1 split · NASDAQ:KTTA · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:KTTA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Pasithea Therapeutics Corp. news

Pasithea Therapeutics Corp. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
23 in the last 12 months · 110 in all · newest Nov 13, 2026 · oldest 2021
Decks
4 decks · latest September 2026

Where Pasithea Therapeutics Corp. is listed

ListingExchangeCountryCurrency
NASDAQ:KTTA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KTTABOATSUnited StatesUSD

Valuation

Price/book 0.4× against a median of 1.7×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$25.22M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
−0.1×
Price/book
0.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.97

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Pasithea Therapeutics Corp. · NASDAQ:KTTAUS$16.00M−US$25.22Mn/an/a−0.1×0.4×n/a0.0×0.97
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.76MUS$15.67Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
Lipocine Inc. · NASDAQ:LPCNUS$16.39M−US$5.07Mn/a−1.4×n/a0.8×−249.2%0.0×1.18
MaaT Pharma · EURONEXT:MAATUS$16.11MUS$23.36Mn/a4.7×n/an/a−686.6%n/an/a
Elicera Therapeutics AB · OMXSTO:ELICUS$16.11MUS$10.42Mn/an/an/a2.9×n/a0.0×n/a
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
Median of the othersUS$16.25MUS$11.52M3.7×1.7×−213.8%0.0×1.18

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.76 · 1 analyst

Team and board

Officers

OfficerRole
Tiago Reis MarquesChief Executive Officer and Director
Daniel SchneidermanChief Financial Officer
Patrick GaynesCorporate Communications
Kartik KrishnanChief Medical Officer
Lawrence SteinmanExecutive Chairman and Co-Founder

Board

DirectorRole
Lawrence SteinmanExecutive Chairman and Co-Founder
Alfred NovakDirector
Daniel R. WeinbergerDirector
Emer LeahyDirector
Simon DumesnilDirector
Tiago Reis MarquesChief Executive Officer and Director

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−4.2%
Q2 2026Aug 14, 2026 · After close−0.6%
Q1 2026Jun 3, 2026−3.9%
Q4 2025Mar 30, 2026 · After close+3.8%
Q3 2025Nov 13, 2025+2.1%
Q2 2025Aug 14, 2025−2.1%
Q1 2025May 15, 2025+0.1%
Q4 2024Mar 24, 2025+0.8%
Q3 2024Dec 27, 2024 · After close+8.1%
Q2 2024Aug 11, 2024 · After close−1.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close0.0%
Q4 2023Mar 28, 2024 · After close0.0%
Q3 2023Dec 29, 2023 · After close
Q2 2023Aug 11, 2023 · After close−1.6%
Q1 2023May 12, 2023 · After close−1.1%
Q4 2022Mar 1, 2023+2.9%
Q3 2022Nov 14, 2022 · After close−2.8%
Q2 2022Aug 15, 2022 · After close−2.3%
Q1 2022May 16, 2022 · After close+9.1%
Q4 2021Mar 30, 2022 · After close−7.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck20 slidesSeptember 2026
IPO Roadshow (August 2021)IPO roadshow17 slidesAug 27, 2021
IPO Roadshow (August 2021)IPO roadshow17 slidesAug 6, 2021
IPO Roadshow (June 2021)IPO roadshow15 slidesJun 22, 2021

Open Decks

Financings

RaiseDate
Public offering of common stock (or pre-funded warrants in lieu thereof)
Closed: US$60M raised · US$0.75 a share · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Vivo Capital; Janus Henderson Investors; Coastlands Capital; Columbia Threadneedle Investments; Adage Capital Partners; Squadron Capital Management
Use of proceeds: General corporate purposes, including research, clinical trials and working capital
Dec 2, 2025
Public offering of common stock (or pre-funded warrants) with Series C and Series D warrants
Closed: US$5M raised · US$1.4 a share · Warrants at US$1.4 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: General corporate purposes, including research, pre-clinical studies, clinical trials, licensing, acquisitions and working capital
May 7, 2025
Warrant exercise of series D warrants
Closed: US$1.3M raised · US$1.4 a share
May 7, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a unit on Sep 14, 2021.

Price
US$5.00 a unit
Units offered
4,800,000 units
Offering size
US$24 million
Underwriters' option
Up to 720,000 more units
Listing
KTTA on the Nasdaq Capital Market
Underwriter
EF HUTTON
Units delivered
On or about Sep 17, 2021

Steps

StepWhen
Filed publiclyApr 13, 2021
Amended 6 timesNewest Sep 13, 2021
Shares registered with an exchangeSep 13, 2021
Declared effective by the SECSep 14, 2021
Final prospectus, with the priceSep 16, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Sep 16, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue00486.6K486.6K15.1K
Cost of revenue662.6K649.0K648.5K113.2K17.3K
Gross profit-662.6K-649.0K-648.5K-5.09K-2.21K
Research and development7.98M7.20M8.10M2.67M0
Selling, general and administrative12.9M7.05M7.88M9.92M4.51M
Operating income-20.9M-14.2M-16.0M-12.6M-4.51M-61.5K
Depreciation and amortization32.4K18.9K18.3K5.09K1.38K61.5K
EBITDA-20.8M-14.2M-16.0M-12.6M-4.51M0
Interest expense1025080
Income before tax-20.4M-13.9M-15.5M-11.7M-2.17M-61.5K
Income tax453.9M-880.0K508-61.5K
Net income-20.4M-13.9M-16.0M-13.9M-2.17M-61.5K
Earnings per share, basic-2.91-12.69-0.42-1.76-0.21-0.09
Earnings per share, diluted-2.91-12.69-0.42-1.76-0.21

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents55.2M6.92M16.3M33.1M53.0M243.7K
Short-term investments6.92B
Receivables40.5K302.1K
Inventory-40.5K1
Current assets56.5M7.37M16.7M34.1M53.3M248.0K
Property, plant and equipment122.3K141.2K125.2K20.1K
Goodwill01.26M1.26M1.26M0
Total assets60.2M16.1M26.1M45.2M53.3M248.0K
Accounts payable1.12M2.55M1.48M447.3K6.60K
Current liabilities4.97M1.12M2.63M1.88M447.3K6.60K
Total debt81.7K504.4K
Total liabilities5.02M1.28M2.72M2.68M1.90M6.60K
Shareholders' equity55.2M14.8M23.4M42.5M51.4M241.4K
Shares outstanding23.1M1.39M1.04M1.30M23.0M688.9K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-15.2M-13.9M-12.8M-14.6M-3.17M-38.7K
Capital spending0-2-34.3K-107.1K-21.5K-1
Free cash flow-15.2M-13.9M-12.8M-14.7M-3.20M-38.7K
Cash from investing11.0K75.2K-2.06M-21.5K-21.5K
Cash from financing63.5M4.52M-3.73M-3.21M55.9M282.3K
Dividends paid-359.7M
Share buybacks0-3.73M-3.21M0
Change in cash48.3M-9.41M-16.8M-19.8M52.7M243.7K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 16, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
8-K · Current reportSep 16, 2026Current reportSEC
25-NSESep 16, 2026Other filingsSEC
8-K · Current reportSep 9, 2026Meeting outcomeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 21, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersAug 7, 2026Annual reportSEC
DEF 14A · Proxy statementAug 7, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementJul 29, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 1, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 23, 2026Big-stake noticeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 5, 2026Insider tradeSEC
8-K · Current reportMay 4, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeApr 22, 2026Big-stake noticeSEC
3 · Initial statement of ownershipApr 17, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 8, 2026Big-stake noticeSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 27, 2026Big-stake noticeSEC
8-K · Current reportFeb 20, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansJan 30, 2026Offer documentSEC
8-K · Current reportJan 28, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveJan 28, 2026Other filingsSEC
POS AM · Amendment to an effective registrationJan 26, 2026Offer documentSEC
DEF 14A · Proxy statementDec 29, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 19, 2025Meeting noticeSEC
8-K · Current reportDec 15, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 5, 2025Big-stake noticeSEC
8-K · Current reportDec 2, 2025Material contractSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
424B4 · ProspectusDec 1, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 1, 2025Other filingsSEC
CORRESP · Letter to the SECNov 26, 2025Other filingsSEC
CORRESP · Letter to the SECNov 26, 2025Other filingsSEC
S-1/A · Registration statement, amendedNov 26, 2025Offer documentSEC
8-K · Current reportNov 25, 2025Current reportSEC
CORRESP · Letter to the SECNov 24, 2025Other filingsSEC
CORRESP · Letter to the SECNov 24, 2025Other filingsSEC
CORRESP · Letter to the SECNov 21, 2025Other filingsSEC
CORRESP · Letter to the SECNov 21, 2025Other filingsSEC
CORRESP · Letter to the SECNov 21, 2025Other filingsSEC
CORRESP · Letter to the SECNov 21, 2025Other filingsSEC
CORRESP · Letter to the SECNov 19, 2025Other filingsSEC
CORRESP · Letter to the SECNov 19, 2025Other filingsSEC
S-1 · Registration statementNov 18, 2025Offer documentSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025Current reportSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
8-K · Current reportOct 27, 2025Management or board changeSEC
8-K · Current reportSep 16, 2025Current reportSEC
S-8 · Registration statement for employee plansSep 9, 2025Offer documentSEC
8-K · Current reportSep 3, 2025Management or board changeSEC
UPLOAD · Letter from the SECSep 2, 2025Other filingsSEC
DRS · Draft registration statementAug 27, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftAug 27, 2025Other filingsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersJul 24, 2025Annual reportSEC
DEF 14A · Proxy statementJul 24, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 14, 2025Meeting noticeSEC
8-K · Current reportJul 11, 2025Current reportSEC
8-K · Current reportJun 27, 2025Current reportSEC
8-K · Current reportJun 20, 2025Current reportSEC
424B5 · ProspectusJun 20, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
144 · Notice of proposed saleMay 14, 2025Other filingsSEC
4 · Change in ownershipMay 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 9, 2025Big-stake noticeSEC
8-K · Current reportMay 7, 2025Material contractSEC
424B4 · ProspectusMay 7, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 7, 2025Other filingsSEC
CORRESP · Letter to the SECMay 1, 2025Other filingsSEC
CORRESP · Letter to the SECMay 1, 2025Other filingsSEC
S-1 · Registration statementMay 1, 2025Offer documentSEC
8-K · Current reportApr 25, 2025Current reportSEC
UPLOAD · Letter from the SECApr 14, 2025Other filingsSEC
DRS · Draft registration statementApr 7, 2025Offer documentSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
424B5 · ProspectusNov 26, 2024Offer documentSEC
8-K · Current reportNov 26, 2024Material contractSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
EFFECT · Notice that a registration is effectiveOct 15, 2024Other filingsSEC
424B3 · ProspectusOct 11, 2024Offer documentSEC
CORRESP · Letter to the SECOct 10, 2024Other filingsSEC
UPLOAD · Letter from the SECOct 10, 2024Other filingsSEC
S-3 · Registration statementOct 7, 2024Offer documentSEC
8-K · Current reportSep 30, 2024Material contractSEC
8-K · Current reportSep 26, 2024Current reportSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportJun 26, 2024Meeting outcomeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
ARS · Annual report to shareholdersMay 28, 2024Annual reportSEC
DEF 14A · Proxy statementMay 28, 2024Meeting noticeSEC
8-K · Current reportMay 14, 2024Current reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
4/A · Change in ownership, amendedApr 5, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 5, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 5, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 5, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 5, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 5, 2024Insider tradeSEC
4/A · Change in ownership, amendedApr 5, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 3, 2024Other filingsSEC
S-8 · Registration statement for employee plansMar 29, 2024Offer documentSEC
POS AM · Amendment to an effective registrationMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
8-K · Current reportJan 18, 2024Current reportSEC
8-K · Current reportJan 2, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialDec 28, 2023Meeting noticeSEC
8-K · Current reportDec 28, 2023Current reportSEC
DEFA14A · Additional proxy materialDec 19, 2023Meeting noticeSEC
8-K · Current reportDec 19, 2023Management or board changeSEC
DEFA14A · Additional proxy materialNov 29, 2023Meeting noticeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
ARS · Annual report to shareholdersOct 26, 2023Annual reportSEC
DEF 14A · Proxy statementOct 26, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 16, 2023Meeting noticeSEC
8-K · Current reportOct 13, 2023Current reportSEC
SC TO-I/ASep 14, 2023Acquisition or disposalSEC
8-K · Current reportSep 14, 2023Current reportSEC
SC TO-I/AAug 24, 2023Acquisition or disposalSEC
SC TO-I/AAug 21, 2023Acquisition or disposalSEC
CORRESP · Letter to the SECAug 21, 2023Other filingsSEC
UPLOAD · Letter from the SECAug 15, 2023Other filingsSEC
SC TO-I/AAug 14, 2023Acquisition or disposalSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
SC TO-IAug 9, 2023Acquisition or disposalSEC
SC TO-CJul 20, 2023Other filingsSEC
8-K · Current reportJul 20, 2023Current reportSEC
8-K · Current reportJul 20, 2023Current reportSEC
3 · Initial statement of ownershipJul 3, 2023Insider tradeSEC
SC 13D · Big-stake noticeJun 7, 2023Big-stake noticeSEC
4/A · Change in ownership, amendedJun 6, 2023Insider tradeSEC
4 · Change in ownershipJun 6, 2023Insider tradeSEC
424B3 · ProspectusJun 6, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 6, 2023Other filingsSEC
CORRESP · Letter to the SECJun 1, 2023Other filingsSEC
UPLOAD · Letter from the SECMay 19, 2023Other filingsSEC
DEL AMMay 17, 2023Other filingsSEC
S-3 · Registration statementMay 12, 2023Offer documentSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
EFFECT · Notice that a registration is effectiveApr 20, 2023Other filingsSEC
CORRESP · Letter to the SECApr 17, 2023Other filingsSEC
10-K/A · Annual report, amendedApr 4, 2023Annual reportSEC
UPLOAD · Letter from the SECApr 4, 2023Other filingsSEC
S-8 · Registration statement for employee plansMar 30, 2023Offer documentSEC
S-3 · Registration statementMar 30, 2023Offer documentSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 10, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
3 · Initial statement of ownershipFeb 14, 2023Insider tradeSEC
8-K · Current reportJan 24, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 13, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJan 10, 2023Big-stake noticeSEC

This page holds 200 of 350 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Pasithea Therapeutics Corp.’s releases · as of Dec 2, 2025

Common shares
33,414,448
Fully diluted
33,414,448

Fully diluted

LineShares
Common shares33,414,448

Warrants and options

Lot
Warrants · US$1.40 · expire about May 2030

Share count over time

CountShares
Nov 22, 202633,414,448

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Janus Henderson3.3M9.0%US$1.63MSep 30, 2026
Cable Car Capital, LP3M8.2%US$1.48MSep 30, 2026
Stonepine Capital Management, LLC2.77M7.5%US$1.37MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.1M5.7%US$1.04MSep 30, 2026
Ameriprise1.38M3.8%US$680KSep 30, 2026
AdvisorShares Investments LLC1.16M3.2%US$572KSep 30, 2026
Vivo Capital, LLC373K1.0%US$184KSep 30, 2026
Vanguard299K0.81%US$147KSep 30, 2026
Persistent Asset Partners Ltd291K0.79%US$143KSep 30, 2026
Geode Capital178K0.48%US$87,753Sep 30, 2026
All 23 holders
HolderSharesOf the companyValueAs of
Jane Street143K0.39%US$70,530Sep 30, 2026
XTX Topco Ltd124K0.34%US$61,104Sep 30, 2026
Hrt Financial LP99,6830.27%US$49,000Sep 30, 2026
Two Sigma50,9070.14%US$25,097Sep 30, 2026
Citadel46,1560.13%US$22,755Sep 30, 2026
State Street40,8000.11%US$20,114Sep 30, 2026
Northern Trust31,4050.09%US$15,483Sep 30, 2026
Tower Research Capital LLC (TRC)6,1760.02%US$3,045Sep 30, 2026
SBI Securities Co., Ltd.1,051<0.01%US$518Sep 30, 2026
RBC275<0.01%Sep 30, 2026
JPMorgan150<0.01%US$74Sep 30, 2026
UBS71<0.01%US$35Sep 30, 2026
Fidelity62<0.01%US$31Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
AdvisorShares Psychedelics ETF938K2.6%US$483KJun 30, 2026
Vanguard Extended Market Index Fund126K0.34%US$65,084Jun 30, 2026
Fidelity Extended Market Index Fund77,6010.21%US$55,508May 31, 2026
Fidelity Nasdaq Composite Index Fund13,4410.04%US$9,614May 31, 2026
Fidelity Series Total Market Index Fund7,9690.02%US$5,700May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Coastlands Capital LP
10% owner
Buy875,000USD 0.47US$411KNov 17, 2026
Coastlands Capital LP
10% owner
Buy583,083USD 0.50US$291KNov 16, 2026
Coastlands Capital LP
10% owner
Buy209,431USD 0.50US$104KNov 13, 2026
Coastlands Capital LP
10% owner
Buy100,000USD 0.53US$53,000Jun 17, 2026

Big stakes

StakeStakeSharesDateFiling
Coastlands Capital LP11.48%3.84MApr 9, 2026Schedule 13G
Vivo Opportunity Fund Holdings, L.P.9.99%9.2MSep 30, 2026Schedule 13G
Adage Capital Management, L.P.9.99%2.33MDec 31, 2025Schedule 13G
Janus Henderson Group PLC9.99%10.2MNov 28, 2025Schedule 13G
Squadron Capital Management LLC9.90%2.33MDec 31, 2025Schedule 13G
Stonepine Capital Management, LLC8.30%2.77MSep 30, 2026Schedule 13G
Funicular Funds, LP7.40%1.84MApr 15, 2026Schedule 13G
Orca Capital AG5.70%371KMay 6, 2025Schedule 13G
Lawrence Steinman3.10%83,858Mar 1, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alfred Novak
Other companies: Dova Pharmaceuticals Inc (Director · Jun 28, 2017 – Nov 12, 2019 · Past); LivaNova PLC (Director · Oct 19, 2015 – Jun 15, 2022 · Past); Cyberonics Inc (Director · Jan 29, 2007 – Oct 19, 2015 · Past)
Director · Since at least Sep 14, 2022
Daniel Schneiderman
Other companies: GridAI Technologies Corp. (CHIEF FINANCIAL OFFICER · Jan 2, 2020 – Jan 3, 2022 · Past); MetaStat Inc (VP OF FINANCE AND SECRETARY · Dec 21, 2012 – Jan 12, 2018 · Past)
Chief Financial Officer · Since at least Aug 12, 2022
Lawrence Steinman
Other companies: BioAtla, Inc. (Director · Since at least Dec 15, 2020); Forum Markets, Incorporated (Director · Since at least Nov 6, 2020)
Director · Since at least Sep 14, 2021
Emer Leahy
Other companies: Intensity Therapeutics, Inc. (CEO · Since at least Jun 29, 2023)
Director · Since at least Sep 14, 2021
Daniel R. WeinbergerDirector · Since at least Nov 4, 2026
Graeme Martin CurrieChief Development Officer · Jul 3, 2023 – Mar 1, 2024 · Past
Kartik KrishnanChief Medical Officer · Since at least May 1, 2026
Luca RastelliSince at least Nov 4, 2026
Patrick GaynesCorporate Communications · Since at least Nov 3, 2026
Simon DumesnilDirector · Since at least Nov 15, 2022
All 13 people
PersonSeat
Stanley GlossChief Financial Officer · Sep 14, 2021 – Sep 14, 2021 · Past
Tiago Reis MarquesChief Executive Officer and Director · Since at least Sep 14, 2021
Yassine BendiabdallahChief Operating Officer, Director · Sep 14, 2021 – Sep 14, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Pasithea Therapeutics Corp.